{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:38:38Z","timestamp":1782830318736,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dalbavancin is a semisynthetic antibiotic used as an alternative to vancomycin for skin infections and osteomyelitis. Its long half-life decreases length of hospitalizations. This study analyzes the effectiveness of Dalbavancin for bacteremia and infective endocarditis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The authors performed a retrospective chart analysis on patients who received Dalbavancin due to being poor candidates for PICC placement, poor candidates for prolonged hospitalization, or who were leaving against medical advice. Their hospitalizations were analyzed and results were compiled using descriptive statistics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our cohort had 22 patients treated with Dalbavancin for bacteremia and 1 for endocarditis. They were treated with IV antibiotics, typically a regimen of at least vancomycin and a cephalosporin, for a median of 6.5 days prior to receiving Dalbavancin. 20 received one dose, while three received two doses. 22 had confirmed culture clearance and one denied repeat culture. There were no reported side effects from the medication, no readmissions for worsened infection, and no deaths from the infection. 15 patients had follow-up visits within 90 days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, patients responded well. The lack of readmission to the hospital indicates possible outpatient treatment. This would help decrease cost and comorbidities of long-term hospital stays. These positive results are limited by small sample size and treatment of other antibiotics prior to receiving Dalbavancin. Further research is required to accurately estimate the efficacy of Dalbavancin on bloodstream infections and endocarditis, but these results are promising especially for patients who are not candidates for long term hospitalization or outpatient IV access.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12941-022-00507-5","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T19:09:28Z","timestamp":1651000168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series"],"prefix":"10.1186","volume":"21","author":[{"given":"Connor","family":"Evins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda E.","family":"Schnee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"507_CR1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2147\/TCRM.S86330","volume":"12","author":"KD Leuthner","year":"2016","unstructured":"Leuthner KD, Buechler KA, Kogan D, et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931\u201340.","journal-title":"Ther Clin Risk Manag"},{"key":"507_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331","author":"U Rappo","year":"2018","unstructured":"Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2018. https:\/\/doi.org\/10.1093\/ofid\/ofy331.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"507_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","volume":"93","author":"TA Almangour","year":"2019","unstructured":"Almangour TA, Perry GK, Terriff CM, et al. Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility. Diagn Microbiol Infect Dis. 2019;93(3):213\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"507_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2146\/ajhp070255","volume":"65","author":"J Bailey","year":"2008","unstructured":"Bailey J, Summers KM. Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm. 2008;65(7):599\u2013610.","journal-title":"Am J Health Syst Pharm"},{"key":"507_CR5","doi-asserted-by":"crossref","unstructured":"Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med. 2010;55(5):401-407.","DOI":"10.1016\/j.annemergmed.2009.03.014"},{"issue":"4","key":"507_CR6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849\u201355.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"507_CR7","doi-asserted-by":"publisher","first-page":"106072","DOI":"10.1016\/j.ijantimicag.2020.106072","volume":"56","author":"T Lampejo","year":"2020","unstructured":"Lampejo T. Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review. Int J Antimicrob Agents. 2020;56(3):106072.","journal-title":"Int J Antimicrob Agents"},{"key":"507_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz028","author":"C Bryson-Cahn","year":"2019","unstructured":"Bryson-Cahn C, Beieler AM, Chan JD, et al. Dalbavancin as secondary therapy for serious\u00a0Staphylococcus aureus\u00a0infections in a vulnerable patient population. Open Forum Infect Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofz028.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"507_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","volume":"18","author":"C Hidalgo-Tenorio","year":"2019","unstructured":"Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18(1):30.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"507_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis. 2018;67(5):795\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"507_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1086\/345476","volume":"36","author":"SE Cosgrove","year":"2003","unstructured":"Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"507_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10096-007-0458-2","volume":"27","author":"EE Hill","year":"2008","unstructured":"Hill EE, Peetermans WE, Vanderschueren S, et al. Methicillin-resistant versus methicillin-sensitive Staphylococcus aureus infective endocarditis. Eur J Clin Microbiol Infect Dis. 2008;27(6):445\u201350.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"507_CR13","unstructured":"Vedamurthy A, Geisler B, Lucier D, et al. Leaving against medical advice after the first episode of bacteremia among persons who inject drugs. Abstract published at Hospital Medicine 2020, Virtual Competition.\u00a0Abstract 161, Journal of Hospital Medicine."},{"key":"507_CR14","unstructured":"Schranz AJ, Li-Tzy W, Wohl D, et al. Abstract 11954: Readmission after discharge against medical advice for persons with opioid-associated infective endocarditis. Circulation. Volume 140,\u00a0Issue Suppl_1: Abstracts From the American Heart Association's 2019 Scientific Sessions November 19, 2019"},{"issue":"12","key":"507_CR15","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3111\/13696998.2015.1078339","volume":"18","author":"V Ektare","year":"2015","unstructured":"Ektare V, Khachatryan A, Xue M, et al. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ. 2015;18(12):1092\u2013101.","journal-title":"J Med Econ"},{"issue":"7","key":"507_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ejim.2013.03.014","volume":"24","author":"RA Seaton","year":"2013","unstructured":"Seaton RA, Barr DA. Outpatient parenteral antibiotic therapy: principles and practice. Eur J Intern Med. 2013;24(7):617\u201323.","journal-title":"Eur J Intern Med"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-022-00507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-022-00507-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-022-00507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T19:10:41Z","timestamp":1651000241000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-022-00507-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["507"],"URL":"https:\/\/doi.org\/10.1186\/s12941-022-00507-5","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The design and protocol of this study was approved by the Prisma Health -Upstate Institutional Review Board (IRB) on July 16th, 2020. The referenced research study received approval under exempt category number 4 in accordance with 45CFR46.104, which does not mandate patient signatures as risk is considered minimal. The IRB protocol number for reference is Pro00096627.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual participants personal data is being published in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this manuscript have no conflicts of interest to disclose for this project. As previously stated, the authors have no financial or personal stake in this project.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}